Speedy Scripts had a word of caution for Amazon as it weighs its push into the multibillion-dollar chemists shop market.
“What [Amazon] will see is the magic isn’t in lower net prices to consumers. It’s clearing the right drug to consumers and helping them navigate the system — all fetiches we’ve built a business over 30 years to do,” Express Scripts CEO Tim Wentworth asserted CNBC on Thursday.
CNBC reported in May that Amazon was hiring in an work to figure out how to break into a market, which Wentworth called extraordinarily competitive. While not a done deal, Wentworth said he is “confident” Amazon is look over an entrance, “as they should be.”
Wentworth said he sees Amazon myriad as a potential partner, rather than as a threat to Express Scripts’ up to date share of the market.
“We have a tremendous e-commerce business with on the verge of $30 billion in mail-service prescriptions being done with digital interfaces,” Wentworth turned.
He said 85 percent of Express Scripts’ prescriptions are filled out online. But when solicit fromed whether he was talking to Amazon, Wentworth dodged the question.
“We talk with all breeds of folks all the time, and I won’t talk about any particular set of conversations,” Wentworth summed.
—CNBC’s Christina Farr and Meg Tirrell contributed to this report.